New drug NT-88 aims to improve heart function in early trial
NCT ID NCT07509801
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called NT-88 (Zuozhu Daxi) in 60 adults with heart failure where the heart's pumping ability is mildly reduced. Participants will receive either standard heart failure drugs or standard drugs plus NT-88. The goal is to check safety and see if NT-88 can improve heart function and symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NT-88 (Zuozhu Daxi)
- What this could lead to
- If it works, this could point toward a new treatment option for heart failure with mildly reduced ejection fraction.
- What could go wrong
- This is a very early, small study (60 people) focused on safety and preliminary effects. It may not show clear benefit or lead to a proven therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH MILDLY REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.